SS-31

Background

SS-31 (also known as elamipretide, formerly Bendavia; sequence D-Arg–dimethylTyr–Lys–Phe–NH₂) is a synthetic mitochondria-targeted tetrapeptide designed to localize to the inner mitochondrial membrane and modulate mitochondrial bioenergetics and oxidative stress.[12] It belongs to the class of small, cell-permeable aromatic–cationic peptides that selectively accumulate in mitochondria due to their positive charge and lipophilicity.[12][15]

The peptide was originally developed in the early 2000s by Szeto and Schiller and is therefore sometimes referred to as a Szeto–Schiller peptide (SS peptide).[11][15] Early preclinical studies in models of burn injury, cardiac ischemia, and hypertensive cardiomyopathy demonstrated that SS-31 could reduce mitochondrial reactive oxygen species (ROS), preserve mitochondrial structure, and attenuate cell death, prompting development as a potential therapeutic for a range of mitochondrial and oxidative stress–mediated diseases.[11][15]

Elamipretide has since entered multiple phase 1–3 clinical trials in indications including primary mitochondrial myopathies, Barth syndrome, heart failure, ischemia–reperfusion injury, and ophthalmologic diseases (e.g., dry age-related macular degeneration and Leber hereditary optic neuropathy).[9] As of the latest publicly available regulatory information, it remains an investigational product without marketing authorization in the United States or European Union.[9]

Mechanism of action

Mitochondrial targeting and cardiolipin interaction

SS-31 is a small, positively charged tetrapeptide that selectively partitions into the mitochondrial inner membrane, driven by the negative membrane potential and its alternating aromatic–cationic motif.[12][15] Biophysical and biochemical studies show that SS-31 binds to cardiolipin, a phospholipid enriched in the inner mitochondrial membrane that is critical for organization of electron transport chain (ETC) supercomplexes and cristae structure.[5][10][12]

In tafazzin-knockdown (TazKD) mice, a model of Barth syndrome characterized by abnormal cardiolipin remodeling, in vivo SS-31 treatment improved cardiac mitochondrial respiratory capacity and promoted respiratory chain supercomplex organization without normalizing the monolysocardiolipin/cardiolipin ratio, supporting a functional interaction with cardiolipin-dependent ETC organization rather than direct correction of lipid composition.[5]

Modulation of oxidative stress and bioenergetics

Across multiple preclinical models, SS-31 reduces mitochondrial ROS production, preserves mitochondrial membrane potential, and increases ATP generation.[11][12][15] In hypertensive cardiomyopathy models (angiotensin II–infused and Gαq-overexpressing mice), SS-31 reduced mitochondrial ROS, prevented mitochondrial depolarization, and attenuated left ventricular hypertrophy and fibrosis, indicating a role in limiting mitochondrial oxidative damage and downstream remodeling.[15]

In burn injury, systemic SS-31 administration decreased oxidized protein levels, reduced apoptosis, and ameliorated endoplasmic reticulum stress in skeletal muscle, consistent with improved mitochondrial redox balance and signaling.[11]

Effects on mitochondrial structure and dynamics

In dermal fibroblasts from patients with dilated cardiomyopathy with ataxia syndrome (DCMA), a mitochondrial cardiomyopathy, mitochondria are fragmented and produce excess ROS.[10] Treatment with SS-31 reversed mitochondrial fragmentation, reduced ROS, and normalized mitochondrial morphology, without measurable changes in bulk cardiolipin composition.[10] These data support a mechanism involving stabilization of cristae structure and fusion–fission balance, likely mediated via cardiolipin-dependent interactions with the inner membrane.

Additional mechanistic observations

Preclinical work has extended SS-31’s actions to other systems:

• In neurodegenerative disease–related models, SS-31 reduced mitochondrial dysfunction induced by α-synuclein oligomers and modulated their membrane binding and aggregation, restoring mitochondrial respiration in neuroblastoma cells.[4]
• In aminoglycoside ototoxicity models, SS-31-conjugated nanoparticles showed mitochondrial-specific accumulation in hair cells, slightly increased and then stabilized mitochondrial membrane potential, and reduced gentamicin uptake, suggesting utility as a mitochondria-targeted drug delivery moiety as well as a direct mitochondrial modulator.[13]

Overall, SS-31 is best characterized as a mitochondria-targeted antioxidant and bioenergetic modulator that binds cardiolipin, stabilizes ETC supercomplexes and cristae, reduces ROS, and supports ATP production.[5][10][11][12][15]

Evidence summary

Cardiovascular and mitochondrial cardiomyopathy models

• Hypertensive cardiomyopathy (J Am Coll Cardiol): In angiotensin II–infused mice and Gαq-overexpressing mice, SS-31 treatment reduced mitochondrial ROS, decreased cardiomyocyte apoptosis, and attenuated cardiac hypertrophy and fibrosis.[15] Functional improvements included better left ventricular systolic performance and reduced diastolic dysfunction. Sample sizes in these preclinical cohorts were modest (typically n≈8–15 per group) but sufficient to demonstrate consistent mitochondrial and structural endpoints.[15]

• Barth syndrome model (tafazzin-knockdown mice): In TazKD mice, chronic SS-31 administration improved cardiac mitochondrial respiration and enhanced respiratory chain supercomplex organization, without normalizing the aberrant monolysocardiolipin/cardiolipin ratio.[5] These findings support SS-31’s ability to functionally compensate for cardiolipin-related defects by stabilizing ETC organization.

• DCMA fibroblasts (Front Cardiovasc Med): In vitro exposure of fibroblasts from four pediatric DCMA patients to SS-31 reversed mitochondrial fragmentation and reduced ROS production, indicating potential disease-modifying effects for mitochondrial cardiomyopathies.[10]

Pulmonary and systemic injury models

• Bleomycin-induced pulmonary fibrosis (mice): In a bleomycin model, daily intraperitoneal SS-31 (5 mg/kg) for 28 days mitigated weight loss, reduced histologic fibrosis (HE and Masson staining), decreased hydroxyproline content, and improved mitochondrial ultrastructure and ATP levels.[8] SS-31 also reduced ROS, myeloperoxidase activity, and proinflammatory cytokines (TNF-α, IL-1β, IL-6), consistent with mitochondrial and anti-inflammatory mechanisms.[8]

• Burn injury (mice): In a mouse burn model, systemic SS-31 reduced skeletal muscle apoptosis, ER stress markers, and oxidized proteins by day 7 post-burn and improved insulin sensitivity in skeletal muscle.[11]

Neurologic and vascular aging models

• Cerebral microhemorrhages and aging (mice): In aged, hypertensive mice, SS-31 was evaluated for protection against cerebral microhemorrhages (CMHs). While treatment did not significantly reduce CMH burden, the study demonstrated feasibility for using SS-31 in aged cerebrovascular models and highlighted a high-throughput imaging pipeline for CMH quantification.[6]

• α-Synuclein and mitochondrial dysfunction (cellular): Preprint data show SS-31 displaces α-synuclein from negatively charged membranes, reduces membrane-induced aggregation, alters fibril morphology, and restores mitochondrial respiration in α-synuclein–treated neuroblastoma cells, suggesting potential relevance to synucleinopathies, though in vivo confirmation is pending.[4]

Mitochondrial-targeted drug delivery and derivatives

SS-31 has been extensively used as a mitochondrial targeting module. In zebrafish hair-cell models, SS-31–conjugated nanoparticles accumulated specifically in hair-cell mitochondria and improved survival against gentamicin toxicity compared with unconjugated controls.[13] Derivative SS-31-like peptides have also been designed with enhanced anti-inflammatory and ATP-boosting properties, underscoring the platform nature of this scaffold.[12]

Human clinical data

Multiple phase 1–3 clinical studies of elamipretide in primary mitochondrial myopathy, Barth syndrome, heart failure, and ophthalmic disorders have been conducted by the developer.[9] Publicly available summaries indicate acceptable short-term safety, but several pivotal trials did not meet primary efficacy endpoints, and detailed peer-reviewed phase 3 results are limited.[9] Thus, robust human efficacy evidence remains incomplete, with most mechanistic and efficacy data derived from preclinical models and early-phase trials.

Clinical and research uses

Investigational clinical indications

Elamipretide is being investigated as a disease-modifying therapy in conditions characterized by mitochondrial dysfunction and oxidative stress, including:

• Primary mitochondrial myopathies and related mitochondrial disorders (systemic administration).[9]
• Barth syndrome, targeting cardiomyopathy and skeletal myopathy.[5][9]
• Heart failure and cardiac ischemia–reperfusion injury, based on anti-oxidative and cardioprotective effects in preclinical models and early clinical studies.[9][15]
• Ophthalmologic diseases such as dry age-related macular degeneration and Leber hereditary optic neuropathy, via local (e.g., subcutaneous or ocular) administration targeting retinal mitochondria.[9]

These indications remain investigational, and use outside clinical trials would be considered off-label and unsupported by regulatory approval.

Preclinical research applications

SS-31 is widely used as a tool compound to probe mitochondrial contributions to:

• Hypertensive and cardiomyopathic remodeling.[15]
• Genetic mitochondrial diseases (e.g., Barth syndrome, DCMA).[5][10]
• Pulmonary fibrosis and systemic inflammatory injury.[8][11]
• Neurodegeneration and vascular cognitive impairment.[4][6]
• Ototoxicity and mitochondrial-targeted drug delivery.[13]

Dosing context

Dosing approaches vary by species, route, and indication; all doses below are experimental and not prescriptive.

• Rodent systemic studies:

  • Bleomycin-induced pulmonary fibrosis: SS-31 5 mg/kg intraperitoneally once daily for 28 days.[8]
  • Burn injury: SS-31 administered systemically (intraperitoneal) in mice at doses reported in the low mg/kg range (exact dose details in the original study; commonly 3–5 mg/kg in similar models).[11]
  • Hypertensive cardiomyopathy: SS-31 given by subcutaneous osmotic minipump or daily injections in the low mg/kg range for several weeks, coinciding with angiotensin II infusion or in Gαq mice.[15]
  • Tafazzin-knockdown mice: chronic systemic SS-31 treatment (dose in mg/kg range) improved cardiac mitochondrial function.[5]

• Cellular experiments: Concentrations typically in the low micromolar range (e.g., 0.1–10 µM) are used to modulate mitochondrial function and ROS in cultured cells and patient-derived fibroblasts.[10][12]

• Clinical trials: Human studies have used intravenous infusions (e.g., peri-ischemic settings) and subcutaneous injections (e.g., chronic mitochondrial disease, heart failure, ophthalmology) with dose levels and schedules defined in specific protocols; overall, exposure durations range from single-dose administration to months of daily dosing.[9] Detailed dosing regimens are not fully standardized and remain trial-specific.

Safety profile

Preclinical safety and tolerability

In animal models, SS-31 has generally been well tolerated at pharmacologically active doses. Rodent and large-animal studies report:

• No major hemodynamic instability or acute toxicity at cardioprotective doses.[15]
• Absence of overt organ toxicity or significant weight loss attributable to the peptide in chronic studies; in some cases (bleomycin model), SS-31 attenuated disease-related weight loss.[8]
• Improvement rather than deterioration of mitochondrial and cellular homeostasis, with reduced oxidative damage and apoptosis.[8][11][15]

Human safety (early-phase trials)

Publicly available clinical trial summaries indicate that elamipretide has an acceptable short-term safety profile, with predominantly mild to moderate adverse events, including:

• Injection-site reactions (erythema, pain).[9]
• Transient gastrointestinal symptoms (nausea) and headache in some participants.[9]

No consistent signals of serious mitochondrial toxicity, arrhythmias, or organ failure have been emphasized in early-phase reports.[9] Long-term safety, particularly in pediatric and genetic mitochondrial populations, remains under active investigation.

Potential adverse effects and uncertainties

Because SS-31 directly modulates mitochondrial function, potential theoretical risks include:

• Unintended alteration of mitochondrial bioenergetics in tissues with high energy demand.
• Interactions with other agents that affect mitochondrial membrane potential or ETC activity.

To date, such effects have not been systematically documented in humans at therapeutic exposures, but comprehensive post-marketing surveillance data are lacking because the drug is not approved.

Regulatory status

Elamipretide (SS-31, Bendavia) is currently an investigational mitochondrial-targeted peptide and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any indication.[9]

• In the United States, elamipretide has been studied under Investigational New Drug (IND) applications in multiple phase 1–3 trials for mitochondrial and cardiovascular indications.[9]
• In the European Union and other regions, development has focused on similar investigational indications, but no centralized marketing authorization has been granted.[9]

Several pivotal trials reportedly did not meet primary efficacy endpoints, contributing to the absence of current approval and highlighting the need for further large, well-controlled studies to clarify clinical benefit.[9] As a result, SS-31 remains confined to controlled clinical trial use and preclinical research settings.